- Home
- BIIB vs YUMC Comparison
BIIB vs YUMC Comparison
Compare BIIB & YUMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- YUMC
- Stock Information
- Founded
- BIIB 1978
- YUMC 1987
- Country
- BIIB United States
- YUMC China
- Employees
- BIIB N/A
- YUMC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- YUMC Restaurants
- Sector
- BIIB Health Care
- YUMC Consumer Discretionary
- Exchange
- BIIB Nasdaq
- YUMC Nasdaq
- Market Cap
- BIIB 18.7B
- YUMC 15.6B
- IPO Year
- BIIB 1991
- YUMC N/A
- Fundamental
- Price
- BIIB $168.22
- YUMC $46.38
- Analyst Decision
- BIIB Buy
- YUMC
- Analyst Count
- BIIB 24
- YUMC 0
- Target Price
- BIIB $174.62
- YUMC N/A
- AVG Volume (30 Days)
- BIIB 1.7M
- YUMC 1.3M
- Earning Date
- BIIB 10-30-2025
- YUMC 11-04-2025
- Dividend Yield
- BIIB N/A
- YUMC 2.07%
- EPS Growth
- BIIB N/A
- YUMC 6.57
- EPS
- BIIB 10.97
- YUMC 2.40
- Revenue
- BIIB $10,065,900,000.00
- YUMC $11,569,000,000.00
- Revenue This Year
- BIIB $2.97
- YUMC $5.94
- Revenue Next Year
- BIIB N/A
- YUMC $5.73
- P/E Ratio
- BIIB $15.01
- YUMC $19.36
- Revenue Growth
- BIIB 4.77
- YUMC 3.29
- 52 Week Low
- BIIB $110.04
- YUMC $41.00
- 52 Week High
- BIIB $175.86
- YUMC $53.99
- Technical
- Relative Strength Index (RSI)
- BIIB 75.35
- YUMC 62.61
- Support Level
- BIIB $151.83
- YUMC $45.83
- Resistance Level
- BIIB $157.79
- YUMC $46.45
- Average True Range (ATR)
- BIIB 5.59
- YUMC 0.87
- MACD
- BIIB 1.43
- YUMC 0.27
- Stochastic Oscillator
- BIIB 98.29
- YUMC 93.35
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About YUMC Yum China Holdings Inc.
With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.